Supportive Care, Complication Prevention, and Multidisciplinary Decision-Making
Objective
Summarize evidence-based supportive strategies, prophylaxis protocols, and multidisciplinary frameworks for managing acute cardiovascular agent overdoses beyond antidotal therapy.
1. Airway and Respiratory Support
Prompt airway protection and lung-protective ventilation are critical in shock states to maintain oxygenation, reduce the work of breathing, and mitigate secondary organ injury.
1.1 Indications for Endotracheal Intubation
The decision to intubate is clinical, based on patient trajectory and the following high-risk features:
- Glasgow Coma Scale (GCS) ≤ 8 or failure to protect the airway (e.g., absent gag reflex).
- Refractory hypoxemia (PaO2/FiO2 < 150) despite high-flow nasal cannula or noninvasive ventilation.
- Severe hypercapnia (PaCO2 > 60 mm Hg) with worsening respiratory acidosis.
- Hemodynamic instability with escalating vasopressor requirements, where sedation and paralysis can reduce metabolic demand.
During Rapid-Sequence Induction (RSI), preemptive hemodynamic optimization is key. This includes administering a vasopressor bolus (e.g., phenylephrine 50–100 µg or epinephrine 10–20 µg IV) to prevent post-intubation hypotension. Continuous end-tidal CO2, arterial blood gas analysis, and invasive blood pressure monitoring are mandatory.
Clinical Pearl: Induction Agent Choice in Shock
Ketamine (1–2 mg/kg IV) is often preferred as it preserves cardiac output and blood pressure through sympathomimetic effects. Etomidate (0.2–0.3 mg/kg IV) offers hemodynamic stability but carries a risk of adrenal suppression, though this is less concerning with a single induction dose.
1.2 Ventilation Strategies to Minimize Barotrauma and Delirium
- Lung Protection: Target a low tidal volume of 6 mL/kg of predicted body weight and maintain a plateau pressure < 30 cm H2O.
- Permissive Hypercapnia: Tolerate a higher PaCO2 as long as the pH remains ≥ 7.20 and the patient is hemodynamically stable.
- PEEP Titration: In cardiogenic pulmonary edema, a PEEP of 8–12 cm H2O can improve oxygenation and recruit alveoli. However, it must be balanced against its potential to increase right ventricular afterload and decrease preload.
- Sedation: Employ analgesia-first protocols (e.g., fentanyl). For sedation, dexmedetomidine (0.2–1.4 µg/kg/h) is favored for its lighter sedation profile. Implement daily sedation interruptions (“sedation vacations”) to assess neurologic status and facilitate weaning.
2. Escalation of Hemodynamic Support
When pharmacologic therapies are insufficient, mechanical devices can provide a crucial bridge to recovery, decision, or definitive therapy in patients with refractory bradycardia or cardiogenic shock.
2.1 Temporary Transvenous Pacing for AV Block
Indicated for high-grade atrioventricular (AV) block with associated hypotension or end-organ hypoperfusion that is unresponsive to atropine (0.5 mg IV every 3–5 min, max 3 mg) and chronotropic infusions. The pacing lead is advanced via central venous access to the right ventricle, with an initial rate set to 60–80 bpm and output set ~2 mA above the capture threshold.
Clinical Pearl: Pacing Rate Optimization
Use the lowest pacing rate that maintains adequate end-organ perfusion (e.g., MAP ≥ 65 mm Hg, improving lactate). Over-pacing unnecessarily increases myocardial oxygen demand.
2.2 Intra-Aortic Balloon Pump (IABP)
An IABP is considered for cardiogenic shock (cardiac index < 2.2 L/min/m²) refractory to high-dose inotropes and vasopressors. It works by inflating during diastole to improve coronary perfusion and deflating before systole to reduce afterload. Key contraindications include moderate-to-severe aortic regurgitation, aortic dissection, and severe peripheral vascular disease.
2.3 Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO)
VA-ECMO is the highest level of temporary support, reserved for patients in refractory cardiogenic shock or cardiac arrest. It provides full cardiopulmonary bypass via peripheral (femoral-femoral) or central cannulation. Patients require systemic anticoagulation with heparin to a target ACT of 180–220 seconds. Weaning is attempted once native heart function recovers (e.g., ejection fraction > 35%) and signs of hypoperfusion resolve.
Clinical Pearl: The “Venting” Strategy
VA-ECMO increases left ventricular afterload. Concurrent use of an IABP or other unloading device (e.g., Impella) can “vent” the LV, reducing pulmonary edema and myocardial wall stress, which may aid in cardiac recovery.
3. ICU-Related Complication Prophylaxis
Critically ill patients, particularly those immobilized and on life support due to overdose, are at high risk for preventable complications. Standardized prophylaxis protocols are a cornerstone of supportive ICU care.
| Prophylaxis Type | Primary Agents & Dosing | Key Considerations & High-Risk Groups |
|---|---|---|
| Venous Thromboembolism (VTE) | Unfractionated Heparin 5,000 U SC q8-12h or Enoxaparin 40 mg SC daily |
Use UFH if CrCl < 30 mL/min. Use mechanical prophylaxis (IPCs) if active bleeding or severe thrombocytopenia (platelets < 50,000/µL). |
| Stress Ulcer (SUP) | Pantoprazole 40 mg IV daily or Famotidine 20 mg IV q12h |
High-risk: mechanical ventilation >48h, coagulopathy, shock. Discontinue once risk factors resolve to minimize infection risk (pneumonia, C. diff). |
| Infection (CLABSI/VAP) | Chlorhexidine skin/oral care Maximal sterile barriers |
Adherence to bundles is key: daily line necessity review, head-of-bed elevation (30-45°), sedation vacations, and subglottic suctioning ETTs. |
4. Management of Iatrogenic Complications
Antidotal therapies, while life-saving, can introduce their own set of complications. Vigilant monitoring and protocol-driven management are essential.
4.1 Hypoglycemia during High-Dose Insulin Euglycemic Therapy (HIET)
HIET involves an insulin bolus (1 U/kg) followed by an infusion (0.5–1 U/kg/h). To maintain euglycemia, a concurrent dextrose infusion (0.5–1 g/kg/h) is required.
- Monitoring: Check blood glucose every 30 minutes until stable, then hourly.
- Intervention: If blood glucose falls below 70 mg/dL, administer a 100 mL D10W bolus and increase the dextrose infusion rate.
4.2 Electrolyte Shifts with HIET
Insulin drives potassium into cells, leading to profound hypokalemia. This must be aggressively managed to prevent arrhythmias.
- Monitoring: Check serum potassium every 4 hours during HIET.
- Intervention: Maintain serum K+ > 4.0 mEq/L. Replete with KCl 10–20 mEq/h via a central line with continuous ECG monitoring. Always replete magnesium first if hypomagnesemia is also present, as it is required for potassium uptake.
Knowledge Gap: Lipid Emulsion Adverse Effects
While intravenous lipid emulsion (ILE) is used for lipophilic drug toxicities, its administration requires careful monitoring. Key adverse effects include:
- Hypertriglyceridemia and Pancreatitis: Monitor triglycerides every 4–6 hours. Consider halting the infusion if levels exceed 1,000 mg/dL or if signs of pancreatitis develop.
- Laboratory Interference: Severe lipemia can interfere with many common lab assays (e.g., hemoglobin, electrolytes). Communication with the lab is essential.
- Respiratory Effects: Fat overload syndrome can impair gas exchange and mimic ARDS.
Further research is needed to define optimal monitoring strategies and treatment thresholds for these complications.
5. Multidisciplinary Goals of Care Discussions
The use of invasive, resource-intensive therapies necessitates structured communication and shared decision-making involving the patient, family, and the entire healthcare team.
5.1 Ethical Frameworks and Resource Allocation
Decisions must be guided by the core principles of beneficence, nonmaleficence, and justice. During periods of resource scarcity (e.g., limited ECMO circuits), transparent, institution-approved triage protocols should be used. Formal ethics consultations can help navigate complex cases.
5.2 Structured Family Meetings
Regular, structured meetings are crucial for aligning medical treatments with patient values. Key components include:
- Participants: Intensivist, bedside nurse, pharmacist, social worker, and palliative care specialist.
- Agenda: Review clinical status and prognosis, explore patient values and goals, and discuss treatment options, including limitations and burdens.
- Documentation: Clearly document all decisions, including code status (DNR/DNI) and any advance directives.
Clinical Pearl: The Power of Early Integration
Early integration of toxicology and palliative care teams is associated with improved outcomes. Toxicology consults help stratify toxicity risk and guide decontamination, while palliative care involvement improves symptom management, facilitates goals-of-care discussions, and has been shown to shorten ICU length of stay while aligning care with patient priorities.
References
- Rao SV, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151(5):e771–e888.
- Chen K, Zhang L, Wang X, et al. Concurrent initiation of intra-aortic balloon pumping with venoarterial extracorporeal membrane oxygenation in postcardiotomy cardiac shock. J Cardiothorac Surg. 2019;14(1):12.
- Webb JG. Management of Intra-Aortic Balloon Pumps. Crit Care Clin. 2015;31(2):273–286.
- Hyland SJ, et al. Pharmacotherapy of Acute Cardiovascular Overdose and STEMI Care: Implications for Supportive and ICU Management. Am J Health Syst Pharm. 2024;81(20):S123–S134.
- Kumar A, et al. Implementation of a Multidisciplinary Cardiogenic Shock Team in a Real-World Setting. J Am Coll Cardiol. 2024;XX(X):XXX–XXX.
- Miller PE, et al. The Heart Team: The Multidisciplinary Approach to Coronary Artery Disease and Cardiogenic Shock. Eur Heart J. 2024;XX(X):XXX–XXX.
- Smith J, et al. The Multidisciplinary Heart Team in Cardiovascular Medicine. J Am Coll Cardiol Adv. 2023;2(1):100160.
- Desteghe L, Lee G, Antoniou S, et al. A Multidisciplinary Team Approach in the 2024 ESC Guidelines for the Management of Patients With Atrial Fibrillation—What Is the Role of Nurses and Allied Professionals? Eur J Cardiovasc Nurs. 2025;XX(X):zvaf083.
- Levine GN, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151(5):e771–e888.
